| Authors: |
El Zarif, T.; Nassar, A. H.; Adib, E.; Fitzgerald, B. G.; Huang, J.; Mouhieddine, T. H.; Rubinstein, P. G.; Nonato, T.; McKay, R. R.; Li, M.; Mittra, A.; Owen, D. H.; Baiocchi, R. A.; Lorentsen, M.; Dittus, C.; Dizman, N.; Falohun, A.; Abdel-Wahab, N.; Diab, A.; Bankapur, A.; Reed, A.; Kim, C.; Arora, A.; Shah, N. J.; El-Am, E.; Kozaily, E.; Abdallah, W.; Al-Hader, A.; Abu Ghazal, B.; Saeed, A.; Drolen, C.; Lechner, M. G.; Drakaki, A.; Baena, J.; Nebhan, C. A.; Haykal, T.; Morse, M. A.; Cortellini, A.; Pinato, D. J.; Dalla Pria, A.; Hall, E.; Bakalov, V.; Bahary, N.; Rajkumar, A.; Mangla, A.; Shah, V.; Singh, P.; Aboubakar Nana, F.; Lopetegui-Lia, N.; Dima, D.; Dobbs, R. W.; Funchain, P.; Saleem, R.; Woodford, R.; Long, G. V.; Menzies, A. M.; Genova, C.; Barletta, G.; Puri, S.; Florou, V.; Idossa, D.; Saponara, M.; Queirolo, P.; Lamberti, G.; Addeo, A.; Bersanelli, M.; Freeman, D.; Xie, W.; Reid, E. G.; Chiao, E. Y.; Sharon, E.; Johnson, D. B.; Ramaswami, R.; Bower, M.; Emu, B.; Marron, T. U.; Choueiri, T. K.; Baden, L. R.; Lurain, K.; Sonpavde, G. P.; Naqash, A. R. |
| Article Title: |
Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium |
| Abstract: |
PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/μL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS. CONCLUSION: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC. |
| Keywords: |
middle aged; retrospective studies; liver cell carcinoma; carcinoma, hepatocellular; liver neoplasms; human immunodeficiency virus infection; carcinoma, non-small-cell lung; lung neoplasms; retrospective study; lung tumor; head and neck neoplasms; liver tumor; head and neck tumor; hiv infections; non small cell lung cancer; head and neck squamous cell carcinoma; immune checkpoint inhibitor; humans; human; male; female; immune checkpoint inhibitors; squamous cell carcinoma of head and neck
|
| Journal Title: |
Journal of Clinical Oncology
|
| Volume: |
41 |
| Issue: |
21 |
| ISSN: |
0732-183X |
| Publisher: |
American Society of Clinical Oncology
|
| Date Published: |
2023-07-20 |
| Start Page: |
3712 |
| End Page: |
3723 |
| Language: |
English |
| DOI: |
10.1200/jco.22.02459
|
| PUBMED: |
37192435
|
| PROVIDER: |
scopus
|
| PMCID: |
PMC10351941
|
| DOI/URL: |
|
| Notes: |
Article -- Source: Scopus |
